Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

Maya Graham Pedersen; Bjarne Kuno Møller; Rasmus O Bak

doi:10.3390/biomedicines10102441

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

Maya Graham Pedersen
, Bjarne Kuno Møller
, Rasmus O Bak

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

15 Citations (Scopus)

Abstract

Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation of the FMS-like tyrosine kinase 3 (FLT3) in malignant T-cells is currently not only being investigated as a prognostic factor, but also as a target for new treatment options. In this review, we provide an overview and discuss different approaches of current anti-FLT3 CAR T-cells under development. In general, these therapies are effective both in vitro and in vivo, however the safety profile still needs to be further investigated. The first clinical trials have been initiated, and the community now awaits clinical evaluation of the approach of targeting FLT3 with CAR T-cells.

Original language	English
Article number	2441
Journal	Biomedicines
Volume	10
Issue	10
Number of pages	15
ISSN	2227-9059
DOIs	https://doi.org/10.3390/biomedicines10102441
Publication status	Published - Oct 2022

Keywords

AML
CAR
CAR T
FLT3
FLT3L
FMS-like tyrosine kinase-3
chimeric antigen receptor
leukemia

Access to Document

10.3390/biomedicines10102441Licence: CC BY

Library access?

Check availability with the Royal Danish Library

Cite this

@article{3dedda3093654f83811db2d5c2fbd170,

title = "Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML",

abstract = "Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation of the FMS-like tyrosine kinase 3 (FLT3) in malignant T-cells is currently not only being investigated as a prognostic factor, but also as a target for new treatment options. In this review, we provide an overview and discuss different approaches of current anti-FLT3 CAR T-cells under development. In general, these therapies are effective both in vitro and in vivo, however the safety profile still needs to be further investigated. The first clinical trials have been initiated, and the community now awaits clinical evaluation of the approach of targeting FLT3 with CAR T-cells.",

keywords = "AML, CAR, CAR T, FLT3, FLT3L, FMS-like tyrosine kinase-3, chimeric antigen receptor, leukemia",

author = "Pedersen, \{Maya Graham\} and M{\o}ller, \{Bjarne Kuno\} and Bak, \{Rasmus O\}",

year = "2022",

month = oct,

doi = "10.3390/biomedicines10102441",

language = "English",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI",

number = "10",

}

TY - JOUR

T1 - Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

AU - Pedersen, Maya Graham

AU - Møller, Bjarne Kuno

AU - Bak, Rasmus O

PY - 2022/10

Y1 - 2022/10

N2 - Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation of the FMS-like tyrosine kinase 3 (FLT3) in malignant T-cells is currently not only being investigated as a prognostic factor, but also as a target for new treatment options. In this review, we provide an overview and discuss different approaches of current anti-FLT3 CAR T-cells under development. In general, these therapies are effective both in vitro and in vivo, however the safety profile still needs to be further investigated. The first clinical trials have been initiated, and the community now awaits clinical evaluation of the approach of targeting FLT3 with CAR T-cells.

AB - Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation of the FMS-like tyrosine kinase 3 (FLT3) in malignant T-cells is currently not only being investigated as a prognostic factor, but also as a target for new treatment options. In this review, we provide an overview and discuss different approaches of current anti-FLT3 CAR T-cells under development. In general, these therapies are effective both in vitro and in vivo, however the safety profile still needs to be further investigated. The first clinical trials have been initiated, and the community now awaits clinical evaluation of the approach of targeting FLT3 with CAR T-cells.

KW - AML

KW - CAR

KW - CAR T

KW - FLT3

KW - FLT3L

KW - FMS-like tyrosine kinase-3

KW - chimeric antigen receptor

KW - leukemia

U2 - 10.3390/biomedicines10102441

DO - 10.3390/biomedicines10102441

M3 - Review

C2 - 36289703

SN - 2227-9059

VL - 10

JO - Biomedicines

JF - Biomedicines

IS - 10

M1 - 2441

ER -

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

Abstract

Keywords

Access to Document

Library access?

Fingerprint

Cite this